Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK

BACKGROUND: Anti-tumour necrosis factor (anti-TNF) therapies are the most commonly used biologics for inflammatory bowel disease (IBD), but for patients with a comorbidity, newer agents may be a more appropriate treatment choice. AIMS: To investigate the impact of comorbidities in patients with IBD,...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbar, Ayesha, Orchard, Tim, Powell, Nick, Selinger, Christian, tibbatts, Clare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Professional Matters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555136/
https://www.ncbi.nlm.nih.gov/pubmed/36250175
http://dx.doi.org/10.1136/flgastro-2021-101995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555136/
https://www.ncbi.nlm.nih.gov/pubmed/36250175
http://dx.doi.org/10.1136/flgastro-2021-101995

Ejemplares similares